Drugs / MV-CHIK
MV-CHIK
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03635086 | Aug 2018 → Jan 2019 | chikungunya | Themis Bioscience GmbH | Completed | Met primary |
| Phase 2 | NCT03101111 | Aug 2017 → Apr 2019 | chikungunya | Themis Bioscience GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02861586 | Aug 2016 → Sep 2017 | chikungunya | Themis Bioscience GmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MV-CHIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02861586 ↗ |
| Known as | Measles Virus-Chikungunya | “The purpose of this study is to investigate immunogenicity and safety of Measles Virus-Chikungunya (MV-CHIK) vaccine in different dose regimens, 28 days after one or two vaccinations.” NCT03635086 ↗ |
| Known as | MV-CHIK vaccine | “MV-CHIK vaccine” NCT03101111 ↗ |
| Modality | Vaccine | “recombinant measles virus vaccine” NCT02861586 ↗ |
| Route | Intramuscular | “60 subjects will receive i.m. vaccinations with MV-CHIK low dose” NCT02861586 ↗ |